LIVN earnings analysis
What we found in LIVN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
LivaNova reported Q1 2026 revenue of $362.3 million, exceeding estimates of $346.8 million by 4.3%, while EPS of $0.40 missed expectations of $0.86. The company increased its full-year 2026 revenue guidance to a growth range of 7% to 8%, reflecting strong performance in the Cardiopulmonary segment, which experienced an 18.3% revenue increase. However, operating margins remained challenged with fluctuating figures.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Exceeds Estimates
- Q1 2026 revenue was $362.3 million, 4.3% higher than the estimated $346.8 million.
- Cardiopulmonary Segment Growth
- The Cardiopulmonary segment saw an 18.3% revenue increase, significantly contributing to total revenues.
- Adjusted EPS Guidance Raised
- The adjusted EPS guidance was increased to $4.20 - $4.30, up from the previous range of $4.15 - $4.25.
- Improved Free Cash Flow
- Free cash flow reached $15.2 million, indicating cash generation capabilities.
- Operating Margin Recovery Signs
- Operating margin improved to 11.5% from a prior negative margin of -98.2% in Q1 2025.
- Full-Year Revenue Guidance Increased
- Full-year 2026 revenue guidance was raised to a growth range of 7% to 8%.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Previous High Losses Affecting Sentiment
- LivaNova reported a diluted EPS of -6.01 for Q1 2025, indicating significant losses from the prior year.
- Regulatory and Legal Risks Persist
- The company remains exposed to regulatory risks associated with its operations and past legal proceedings.
- Ongoing Market Risks and Foreign Operations Exposure
- LivaNova's operations are exposed to foreign currency exchange risks, as noted in their risk management disclosures.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.4
- Operating margin
- 11.5%
What they said about what is next.
Revenue guidance increased to 7-8% growth, EPS adjusted to $4.20-$4.30.
The filing reads about the same as the one before it.
What came before.
- 10-K · February 25, 2026
- LivaNova reported full-year 2025 net revenue of $1,388,053,000, up 10.7% from $1,253,437,000 in 2024, with operating income rising to $199,390,000 (14.4% operating margin) from $129,051,000 (10.3%). The company…
- 10-Q · August 6, 2025
- LivaNova reported a strong operational quarter with net revenue of $352,524,000, up 10.7% year-over-year, and operating income of $54,183,000 (15.4% operating margin) driving diluted EPS of $0.50 (vs $0.30 prior year).…
- 10-Q · May 7, 2025
- LivaNova reported Q1 net revenue of $316,855,000, up 7.4% year-over-year, with gross profit of $220,775,000 (69.7% gross margin) and operating income improving to $48,617,000. The quarter produced a large, one-time…
- 10-Q · August 1, 2024
- LivaNova reported Q2 net revenue of $318.6M, up 8.4% year-over-year, with gross profit of $218.9M and operating income of $40.2M for the quarter. The quarter delivered diluted EPS of $0.30 and materially stronger…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing LIVN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever